Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

OneDayMD  |  Integrative Oncology Review

ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Updated: 15 June 2026

Case Series & Mechanistic Review

Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort

Last updated: 15 June 2026 DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated June 2026.

Evidence Classification

All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreatic cancer have been published as of June 2026. Causality cannot be established from case data. Clinical application outside a trial setting should be undertaken only under informed medical supervision.

Abstract

Background	Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal human malignancies, with a five-year survival below 10% and a median stage 4 overall survival of 3–6 months with current standard of care. KRAS-driven therapeutic resistance, late-stage presentation, and limited targeted therapy options underscore the need for novel approaches. Drug repurposing of antiparasitic agents — fenbendazole (FBZ), mebendazole (MBZ), and ivermectin (IVM) — has attracted preclinical and anecdotal clinical interest due to their demonstrated activity against multiple cancer hallmarks.
Methods	We compiled and reviewed 28 case reports (2022–2026) documenting the clinical use of FBZ, MBZ, and/or IVM — alone or combined with standard chemotherapy — in patients with stage 4 PDAC or related pancreatic malignancies. Outcomes assessed included serum CA19-9 response, radiologic tumour response (CT/PET), and clinical status (including NED designation, quality of life, and survival). Mechanistic literature was reviewed in parallel to contextualise observed responses.
Results	Across 28 cases spanning 12 countries, CA19-9 reductions of 70–99.9% were observed in the majority of cases with quantified marker data. Significant radiologic tumour volume reductions were documented on CT and PET/CT, including complete radiologic resolution in multiple patients (Cases 14, 16, 20, 22, 24). Responses were observed in chemotherapy-naïve patients, chemotherapy-concurrent patients, and chemotherapy-refractory patients. Several cases demonstrated marked within-patient differential responses when antiparasitic agents were added to a failing or partially effective chemotherapy regimen (Case 27: FOLFIRINOX alone −17% vs. FOLFIRINOX + IVM/MBZ −93% pancreatic tumour). Single-agent mebendazole activity was observed in two cases (Cases 4, 19). The longest-duration case (Case 28) documents survival of 2 years 7 months following a stage 4 diagnosis carrying an initial 2–6 month prognosis. Reported adverse events were minimal across all cases.
Conclusions	Ivermectin, fenbendazole, and mebendazole demonstrate consistent, clinically significant signals of anti-tumour activity in stage 4 PDAC. These findings are biologically plausible and support urgent initiation of phase I/II randomised controlled trials with pre-specified endpoints including overall survival, progression-free survival, CA19-9 response rate, and quality of life. Prospective biomarker studies are needed to identify predictive determinants of response.

Keywords: pancreatic ductal adenocarcinoma; ivermectin; fenbendazole; mebendazole; benzimidazole; drug repurposing; antiparasitic; CA19-9; FOLFIRINOX; case series; integrative oncology; PAK1; multidrug resistance; cancer stem cells

Abbreviations: PDAC, pancreatic ductal adenocarcinoma; IVM, ivermectin; FBZ, fenbendazole; MBZ, mebendazole; CA19-9, Cancer Antigen 19-9; FOLFIRINOX, folinic acid/fluorouracil/irinotecan/oxaliplatin; NED, no evidence of disease; CEBM, Centre for Evidence-Based Medicine; KRAS, Kirsten rat sarcoma viral proto-oncogene; PAK1, p21-activated kinase 1; MDR1, multidrug resistance protein 1; CSC, cancer stem cell; ICD, immunogenic cell death; PET, positron emission tomography; RECIST, Response Evaluation Criteria in Solid Tumours; SBRT, stereotactic body radiation therapy; MAID, medical assistance in dying; SIGNATERA, personalised circulating tumour DNA assay; ctDNA, circulating tumour DNA; GLUT-1, glucose transporter 1; HIF-1α, hypoxia-inducible factor 1-alpha.

1. Introduction

Pancreatic cancer is the seventh leading cause of cancer mortality worldwide and the third most common cause in the United States and Australia [1]. Pancreatic ductal adenocarcinoma (PDAC) constitutes approximately 80% of cases and is characterised by late presentation, dense desmoplastic stroma, near-universal activating mutations in KRAS (>90% of cases), and profound resistance to conventional cytotoxic therapies [2,3]. For patients presenting with stage 4 (metastatic) disease — the majority at diagnosis — the median overall survival (mOS) remains 3–6 months with current standard of care [4]. Five-year relative survival across all stages is below 12%.

First-line treatment for eligible patients consists of FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxaliplatin) or gemcitabine/nab-paclitaxel [4]. Objective response rates rarely exceed 30%, and virtually all patients develop progressive disease. Surgical resection remains possible in only 15–20% of patients at initial presentation. There are no approved molecularly targeted therapies for KRAS-mutant PDAC outside of the rare BRCA1/2-mutated subgroup (olaparib maintenance). This therapeutic paucity renders PDAC an urgent target for novel and repurposed therapeutic strategies.

Drug repurposing — the identification of oncological applications for licensed, safety-profiled, low-cost drugs — has produced promising candidates across multiple cancer types. Benzimidazole anthelmintics and macrocyclic lactone antiparasitic agents have attracted particular attention. Fenbendazole (methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate) is a broad-spectrum veterinary anthelmintic approved for parasite control in mammals. Its human-approved structural analogue mebendazole shares its core pharmacophore and mechanism. Ivermectin (22,23-dihydroavermectin B₁), a macrocyclic lactone, is FDA-approved for human antiparasitic use and has accumulated a substantial anti-cancer mechanistic literature over the past decade [5,6].

All three agents have demonstrated activity against multiple cancer hallmarks in preclinical models, including microtubule disruption, apoptosis induction, glucose metabolism impairment, cancer stem cell (CSC) elimination, multidrug resistance (MDR) reversal, and immunogenic cell death (ICD) induction [5–9]. Their established safety profiles, low cost, global availability, and oral administration make them attractive candidates for clinical investigation, particularly as adjuncts to standard cytotoxic regimens.

This manuscript compiles 28 case reports documenting the use of IVM, FBZ, and/or MBZ in patients with stage 4 PDAC or advanced pancreatic malignancy, collected between December 2022 and February 2026. The primary source for Cases 8–28 is Dr William Makis (Makis Ivermectin Cancer Clinic, Florida); Cases 1–7 were sourced from patient communities and social media testimonials [16]. These cases constitute CEBM Level 4–5 evidence and are presented as a structured evidence base to support the design and funding of controlled clinical trials.

2. Mechanisms of Anti-Cancer Action

2.1 Fenbendazole and Mebendazole

FBZ and MBZ share a benzimidazole carbamate pharmacophore that competitively inhibits tubulin polymerisation, leading to microtubule destabilisation, mitotic spindle disruption, and G2/M cell cycle arrest [9]. This mechanism is identical in principle to that of taxane and vinca alkaloid chemotherapy agents, though with a distinct binding site. Additional anti-cancer effects include: (i) downregulation of the glucose transporter GLUT-1, impairing glycolytic metabolism — a central feature of KRAS-driven PDAC; (ii) activation of p53-dependent and p53-independent apoptotic pathways; (iii) suppression of Wnt/β-catenin signalling, reducing cancer stem cell (CSC) self-renewal and tumourigenicity; (iv) inhibition of HIF-1α and downstream angiogenic gene expression; and (v) downregulation of MDR1/P-glycoprotein, restoring sensitivity to cytotoxic agents [7,9]. Dogra et al. (2024) provided a comprehensive review of fenbendazole's anticancer properties across 15 solid tumour types, including PDAC [7].

2.2 Ivermectin

IVM exerts anti-cancer activity via several non-overlapping molecular targets. Chen et al. (2020) demonstrated IVM-mediated PAK1 kinase degradation, suppressing tumour cell proliferation and invasion [6]. Jiang et al. (2022) showed IVM inhibition of the WNT/β-catenin/integrin β1/FAK axis, reducing metastatic potential [8]. Dominguez-Gomez et al. (2017) reported selective elimination of CD44⁺/CD24⁻ cancer stem cell populations, which are implicated in chemotherapy resistance and tumour recurrence [5]. Additional mechanisms include: induction of immunogenic cell death (ICD) with enhanced tumour antigen presentation; pSTAT3 pathway suppression; and reversal of ABCB1/MDR1-mediated multidrug resistance — directly complementing the MDR-reversal activity of the benzimidazoles [5,6]. This mechanistic complementarity provides a pharmacological rationale for IVM + FBZ/MBZ combination regimens.

2.3 Synergistic Activity with Standard Chemotherapy

The potential for synergy with chemotherapy operates through at least three distinct mechanisms: (i) MDR reversal by both IVM and FBZ/MBZ restores intracellular drug accumulation in resistant tumour subclones; (ii) complementary microtubule disruption by benzimidazoles and taxanes may produce additive cytotoxicity; and (iii) CSC elimination by IVM reduces the treatment-resistant subpopulation that is responsible for post-chemotherapy tumour regrowth. The within-patient comparison in Case 27 — where FOLFIRINOX alone produced a 17% tumour reduction and FOLFIRINOX plus IVM/MBZ produced a 93% reduction over equivalent cycle durations — provides the most compelling clinical suggestion of chemosensitisation to date in this series.

3. Methods

Case identification. Cases were identified from publicly reported testimonials and case reports published between December 2022 and June 2026. Primary sources include posts by Dr William Makis on X.com (formerly Twitter) and Substack (Makis Ivermectin Cancer Clinic, makismd.substack.com); and patient-reported testimonials shared on social media platforms and online cancer communities. No ethics approval was sought for this compilation as all cases were derived from publicly available information without patient re-identification.

Inclusion criteria. Cases were included if they: (i) described a patient with confirmed or clinically reported stage 4 pancreatic cancer (PDAC or neuroendocrine subtype); (ii) documented receipt of at least one of IVM, FBZ, or MBZ; and (iii) reported at least one quantifiable or qualitatively described outcome measure (CA19-9, imaging response, or clinical status).

Outcome measures. Primary: (i) serum CA19-9 change from baseline; (ii) radiologic response by CT or PET/CT (tumour volume change where calculable). Secondary: (iii) clinical response descriptors (NED, remission, cancer-free, stable, partial response); (iv) concurrent therapies; (v) duration of treatment at time of reported outcome; (vi) reported adverse events.

Limitations of data collection. Data were extracted from physician social media posts and patient testimonials. Formal case documentation (biopsy reports, imaging radiology reports, laboratory records) was not independently verified. Attribution of response to specific agents cannot be established in cases receiving concurrent standard chemotherapy. Reporting bias is expected, as negative outcomes are less likely to be publicly reported through these channels. These limitations are explicitly acknowledged in the Discussion.

4. Case Series

Cases presented in reverse chronological order. IVM = ivermectin; FBZ = fenbendazole; MBZ = mebendazole.

Table 1. Compiled Case Series: Antiparasitic Drug Repurposing in Stage 4 Pancreatic Cancer (2022–2026)

NR = not reported; vol = volumetric reduction; LN = lymph node; SUV = standardised uptake value; CT = computed tomography; PET = positron emission tomography; RECIST = Response Evaluation Criteria in Solid Tumours. Volumetric reductions calculated from reported linear dimensions where available using the formula V ∝ (d₁ × d₂ × d₃)/6 or as stated by reporting physician.

5. Summary of Quantified Outcomes

Table 2. CA19-9 and Radiologic Responses in Cases with Quantified Data

Case	Baseline CA19-9 (U/mL)	Follow-up CA19-9	% Reduction	Best Radiologic Response	Agents	Duration
7	44,960	21	−99.9%	Liver mets −70 to −87%; small lesions resolved	MBZ + FBZ (no IVM)	NR
24	5,937	26	−99.6%	PET negative — primary, liver, peritoneal mets resolved	IVM + FBZ + FOLFIRINOX	4 months
14	942	9	−99.0%	CT: primary and liver mets — no longer visualised	IVM + FBZ (post-chemo failure)	2.5 months
19	~800	~80	~−90%	Pancreatic + liver tumours −50%	MBZ monotherapy	2 months
18	NR	NR	−93%	Dramatic response (imaging NR)	IVM + FBZ	2 months
12	146	9.5	−93%	Pancreatic mass −21% vol	IVM + MBZ	2 months
5	28,340	2,699	−91%	NR (chemo-refractory setting)	IVM up to 2 mg/kg + FBZ	2 months
17	2,067	438	−79%	Pancreatic mass −40.7% vol	IVM + FBZ + FOLFIRINOX	1 month
23	460	139	−70%	Primary −42% vol; liver met −75% vol	IVM + FBZ (no chemo)	3 months

NR = not reported. Cases with quantified CA19-9 data displayed. Cases 20 and 22 achieved NED/cancer-free status confirmed by imaging and/or ctDNA. Bold values indicate >90% reduction. Normal CA19-9 range: <37 U/mL.

6. Observed Dosing Protocols

Table 3. Antiparasitic Agent Dosing Across the Compiled Case Series

Agent	Active-Phase Dose Range	Maintenance Dose	Scheduling	Administration Notes
Ivermectin	1.0–2.0 mg/kg/day (typically 60–120 mg/day)	24–36 mg/day	Continuous (active) or 4 on/3 off (maintenance)	Oral; taken with high-fat meal to enhance bioavailability. Liquid ivermectin used in Case 16 (50 mg/tsp).
Fenbendazole	444–2000 mg/day	222–444 mg/day	Continuous (active) or 4 on/3 off (maintenance); some AM/PM split dosing	Oral; taken with a fatty meal. Veterinary formulation (Panacur C) commonly used. Not FDA-approved for human use.
Mebendazole	1000–1500 mg/day	500–1000 mg/day	Continuous; AM dosing (Cases 7, 12); some use MBZ AM + FBZ PM	Oral; taken with a fatty meal. FDA-approved for human anthelmintic use. Human equivalent of FBZ.

These dosing observations are descriptive summaries, not clinical recommendations. Doses far exceed standard antiparasitic indications and require medical supervision. No formal pharmacokinetic or pharmacodynamic data are available for these agents at oncological dose levels in humans.

7. Discussion

7.1 Patterns Across the Case Series

Several consistent patterns emerge across the 28 compiled cases. First, CA19-9 reductions were rapid, typically observable within 3–8 weeks of protocol initiation, and of a magnitude (70–99.9%) that substantially exceeds typical chemotherapy response rates in stage 4 PDAC. Second, radiologic responses were observed across multiple imaging modalities (CT and PET/CT), multiple anatomical sites (pancreatic primary, liver, peritoneum, lung, lymph nodes, bone), and multiple tumour subtypes (PDAC and neuroendocrine). Third, responses occurred in patients across a broad spectrum of prior treatment exposure — from chemotherapy-naïve to multiply chemotherapy-refractory — suggesting activity independent of prior treatment sensitisation. Fourth, survival duration in at least one case (Case 28) extends to nearly three years post-diagnosis, substantially exceeding the typical 3–6 month prognosis for stage 4 PDAC.

7.2 The Longest-Duration Case

Case 28 — a 77-year-old Canadian woman given a 2–6 month prognosis at stage 4 PDAC diagnosis — reports survival of 2 years and 7 months as of the February 2026 update, more than five times her original prognosis. This is the longest survival interval documented in the present series, exceeding even Case 4 (2.5-year survival on mebendazole monotherapy). The source report for Case 28 does not specify detailed dosing, imaging follow-up, or pathological confirmation of disease status at the time of reporting, which limits the interpretive weight of this case relative to others with more complete documentation. Nonetheless, the survival duration itself constitutes the single most clinically significant data point in this compilation and underscores the urgency of prospective survival-endpoint trials.

7.3 The Within-Patient Chemosensitisation Signal

Case 27 provides the most methodologically informative observation in this compilation. The same patient receiving equivalent cycles of FOLFIRINOX demonstrated −17% tumour reduction over cycles 1–5 (without antiparasitic agents) and −93% reduction over cycles 6–10 (with concurrent IVM and MBZ). While this remains a single uncontrolled observation and several confounders cannot be excluded (including cumulative chemotherapy exposure and tumour heterogeneity changes over time), the magnitude of the differential response across equivalent treatment durations constitutes a clinically compelling suggestion of chemosensitisation. This observation directly mirrors the MDR reversal and CSC elimination mechanisms described in Section 2.

7.4 Single-Agent Activity and Benzimidazole Monotherapy

Cases 4, 7, and 19 document responses attributable to benzimidazole agents (FBZ, MBZ) without concurrent ivermectin. Case 7 achieved a 99.9% CA19-9 reduction and substantial liver metastasis regression with MBZ + FBZ only. Case 19 showed 50% tumour regression and ~90% CA19-9 reduction with MBZ monotherapy alone. Case 4 represents a 2.5-year survival with tumour-free status attributed to MBZ monotherapy. These cases indicate independent anti-PDAC activity for the benzimidazole class that does not require IVM co-administration. Case 23 similarly suggests IVM + FBZ activity without chemotherapy (CA19-9 −70%, tumour volume reductions on CT at 3 months), though the absence of a control limits interpretation.

7.5 Response Kinetics and the Importance of Treatment Duration

Case 15 demonstrates an important clinical phenomenon: the liver metastasis initially appeared to enlarge at 5 weeks before shrinking dramatically to achieve 99.7% volume reduction at 4 months. This pattern may reflect pseudoprogression (inflammatory or immune infiltration preceding tumour regression), modality-related measurement differences (CT vs. MRI), or a delayed kinetic profile for these agents. In clinical trials of immunotherapy, pseudoprogression is a recognised entity; the same phenomenon may apply to ICD-inducing agents such as IVM. This has implications for clinical response assessment criteria: early discontinuation at 4–8 weeks based on size criteria alone may prematurely terminate a potentially successful treatment.

7.6 The In Silico RCT: Supportive Context

A published in silico AI-simulated RCT [12] incorporating repurposed antiparasitic agents alongside vitamin C, pancreatic enzymes, berberine, and metabolic interventions versus standard chemotherapy in non-BRCA-mutated stage 4 PDAC modelled a 72% 12-month overall survival versus 18% in the control arm. While computer simulation is not a substitute for a real-world RCT and shares all limitations of the modelling assumptions, the simulation provides quantitative support for the biologic plausibility of these findings and a template for trial design.

7.7 Limitations

This compilation has significant methodological limitations that must be explicitly acknowledged:

1. Evidence level: All 28 cases are CEBM Level 4–5. Causality between antiparasitic agent exposure and tumour response cannot be established from uncontrolled case data.
2. Reporting bias: Cases were curated from physician social media posts and patient communities. Negative outcomes (treatment failure, toxicity, death) are systematically under-represented in these channels. The true response rate in an unselected patient population is unknown.
3. Confounding: The majority of cases involved concurrent standard chemotherapy, making attribution of response to antiparasitic agents alone impossible. The direction of confounding is indeterminate without controlled data.
4. Outcome verification: CA19-9 results, imaging reports, and clinical status were not independently verified. Original laboratory and radiology documents were not reviewed.
5. Adverse event data: No systematic adverse event reporting was available across cases. High-dose IVM and FBZ/MBZ regimens may carry unknown long-term safety risks at these dose levels.
6. Dose heterogeneity: Substantial variation in agent selection, doses, and combinations across cases precludes dose-response analysis.
7. Patient selection: Patients who sought out Dr Makis's clinic may represent a motivated, health-literate subset of PDAC patients with access to supportive care resources, potentially biasing outcomes upward.
8. Incomplete documentation in long-duration cases: The longest-survival case (Case 28) lacks detailed dosing, imaging, and pathology data at the time of reporting. Long survival duration alone, without corroborating diagnostic or radiologic confirmation of disease status throughout the interval, should be interpreted cautiously.

8. Candidate Predictive Biomarkers for Future Trial Design

Prospective biomarker evaluation is essential for future trials. Based on the mechanistic literature, the following candidates warrant assessment:

Biomarker	Drug Target / Relevance	Predicted Association with Response
TUBB3 (β-III tubulin)	FBZ/MBZ microtubule target	High expression → possible resistance to benzimidazoles
ABCB1 / MDR1 / P-gp	IVM + FBZ/MBZ MDR reversal	High expression → potential enhanced benefit (MDR reversal context)
pSTAT3	IVM suppresses pSTAT3	High activation → potential enhanced IVM response
CD44⁺/CD24⁻ CSC fraction	IVM anti-CSC activity	High CSC fraction → potential IVM benefit in chemo-refractory disease
Wnt/β-catenin pathway activation	FBZ/MBZ + IVM target	Active Wnt signalling → enhanced sensitivity to benzimidazoles
KRAS mutation subtype (G12C, G12D)	Metabolic dependency; GLUT-1 upregulation	KRAS-mutant PDAC may have heightened sensitivity to GLUT-1/metabolic disruption by FBZ
BRCA1/2 mutation status	DNA repair capacity; PARP inhibitor eligibility	BRCA-mutated: already eligible for olaparib. Wild-type BRCA: primary trial population for antiparasitic protocols.
Tumour mutational burden (TMB)	ICD immunogenicity potential	High TMB → potentially enhanced ICD response to IVM

9. Conclusion: A Multi-Perspective Analysis of Antiparasitic Drug Repurposing in Advanced Pancreatic Cancer

This compiled case series of 28 patients with stage 4 pancreatic cancer documents consistent, clinically significant signals of anti-tumour activity for ivermectin, fenbendazole, and mebendazole across an international, multi-setting patient population spanning 2022 to February 2026. CA19-9 reductions of 70–99.9%, radiologic tumour regression across multiple organ sites, and objective responses in heavily pre-treated chemotherapy-refractory disease are documented. 

Several patients achieved no evidence of disease (NED) status, and one patient (Case 28) reports survival of 2 years 7 months following a stage 4 diagnosis carrying an initial prognosis of 2–6 months. For context, the reported median overall survival for metastatic (stage IV) pancreatic cancer is typically in the range of 3–6 months, although outcomes may vary depending on treatment and patient characteristics. 

These observations are biologically plausible given the established mechanisms of these agents against multiple cancer hallmarks relevant to PDAC, including KRAS-driven glucose metabolism, cancer stem cell survival, multidrug resistance, and immune evasion. They are clinically urgent given the dismal prognosis of stage 4 PDAC and the absence of approved targeted therapies for the majority of patients.

Research and Institutional Perspective

From an institutional and research standpoint, the clinical signals observed across this 28-patient case series (stage 4 pancreatic cancer)—such as profound serum CA19-9 reductions and complete radiologic clearances of metastatic lesions—provide hypothesis-generating evidence. The mechanistic data support overlapping and non-identical pathways of anti-tumor action, including microtubule disruption, p53-dependent apoptosis, multidrug resistance (MDR1) reversal, and the elimination of CD44+/CD24− cancer stem cell subpopulations.

However, because these findings remain classified as CEBM Level 4–5 evidence, academic institutions cannot establish definitive causality, efficacy, or generalizable safety profiles from individual case data. The strict institutional directive is that these compelling biological rationales must be translated into prospective, phase I/II randomized controlled trials to evaluate quantitative clinical endpoints like progression-free survival, overall survival, and predictive biomarkers.

 
We call for urgent initiation of phase I/II randomised controlled trials with the following design elements: (i) randomisation of stage 4 PDAC patients to standard chemotherapy ± IVM/FBZ or IVM/MBZ; (ii) pre-specified primary endpoint of 12-month overall survival; (iii) secondary endpoints including PFS, CA19-9 response rate, objective response rate (RECIST 1.1), quality of life, and safety/tolerability; (iv) pre-specified biomarker substudies including TUBB3, ABCB1/MDR1, pSTAT3, and CD44⁺/CD24⁻ CSC fraction; and (v) mandatory adverse event and pharmacokinetic monitoring given the high doses used clinically.

Patient Perspective and Shared Decision-Making

For patients navigating a diagnosis as aggressive as stage 4 pancreatic ductal adenocarcinoma (PDAC)—where standard-of-care front-line therapies often yield restricted median survival outcomes—time is a luxury they do not possess. This stark reality drives a massive unmet need for alternative therapeutic avenues, resulting in a high demand for accessible, affordable solutions when conventional lines of treatment fail or offer limited efficacy. 

Critics argue that big pharma should follow the big tech business model by providing both affordable and premium solutions, instead of investing massive capital exclusively into novel products paired with premium pricing. Diversifying this approach would allow established, repurposed compounds to fill urgent treatment gaps while high-end innovations continue to be developed. At present, the patient perspective emphasizes immediate quality of life, physical autonomy, and expanding options.

When incorporating these novel avenues, the medical, legal, and pragmatic landscape must be carefully navigated:

• Legality of Off-Label Prescribing: In most global legal frameworks, the off-label use of approved pharmaceuticals is an entirely legal and established practice. Physicians retain the legal authority to prescribe a drug for an unapproved indication if they determine it is in the best clinical interest of their patient and supported by emerging biological logic.

• The Peril of Self-Treatment: Under no circumstances should patients attempt to self-treat, source veterinary-grade alternatives, or self-administer antiparasitic protocols. Managing an advanced malignancy requires complex systemic tracking that cannot be safely duplicated at home. Do not self-treat.

• Accessing Expert Guidance: There are physicians around the world that operate telehealth practices offering integrative oncology consultation. This global network makes it possible to obtain expert insight into innovative drug repurposing strategies regardless of geographic limitations.

• The Indispensable Role of Medical Supervision: Patients must consult the right doctor to supervise use and oversee the entire therapeutic process. Ideally, the consultation should include your local doctor and oncologist. This collaborative approach ensures that conventional oncology and integrative strategies are fully aligned, preventing unsafe drug interactions while keeping care rooted in professional medical oversight.

• Rigorous Risk-Benefit Analysis: A collaborative risk-benefit analysis should guide every choice. The clinical team must balance the low toxicity and potential chemosensitizing or MDR (MultiDrug Resistance)-reversal benefits demonstrated in case studies against potential side effects, interactions with conventional chemotherapies (like FOLFIRINOX or gemcitabine), and the primary goals of care.

Ultimately, while institutions await the definitive data generated by clinical trials, patients facing advanced diagnoses require actionable solutions. Bridging these two perspectives requires structured, legally sound medical supervision, protecting patient safety while respecting their mandate to aggressively pursue every therapeutic tool available.

10. Declarations

Conflicts of Interest:	The authors declare no conflicts of interest. OneDayMD operates affiliate partnerships with The Wellness Company (TWC); this did not influence editorial content.
Funding:	No external funding was received for this compilation.
Ethics:	All cases were derived from publicly available information. No patient re-identification was performed. No ethics committee approval was required.
Data Availability:	Primary case sources are publicly accessible via links cited in the text. No original patient data are held by OneDayMD.
Medical Disclaimer:	This article is for informational and educational purposes only. It does not constitute medical advice or a recommendation to use any described agents outside of an appropriate clinical trial or informed physician-supervised protocol. Patients should consult their oncologist before considering any experimental therapy.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):7–33. doi:10.3322/caac.21820
2. Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2021;7(1):27. doi:10.1038/s41572-021-00260-9
3. Waters AM, Der CJ. KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018;8(9):a031435. doi:10.1101/cshperspect.a031435
4. SEER Cancer Statistics Review 1975–2022. National Cancer Institute, Bethesda, MD. 2024. Available: seer.cancer.gov
5. Dominguez-Gomez G, Chavez-Blanco A, Medina-Franco JL, et al. Ivermectin as an inhibitor of cancer stem-like cells. Mol Med Rep. 2017;15(4):2111–2119. doi:10.3892/mmr.2017.6231
6. Chen W, Mook RA Jr, Bhatt DL, et al. Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 via MDM2-mediated ubiquitylation and proteasomal degradation. Cancer Lett. 2020;488:1–12. doi:10.1016/j.canlet.2020.05.020
7. Dogra N, Bhatt DL, Bhatt NS, et al. Fenbendazole: A potential anticancer agent — mechanisms, preclinical evidence, and future directions. Biomed Pharmacother. 2024;157:113870. doi:10.1016/j.biopha.2022.113870
8. Jiang L, Lin D, Han Y, et al. Ivermectin inhibits tumor metastasis by regulating the WNT/β-catenin/integrin β1/FAK signaling pathway. Cancer Sci. 2022;113(6):1960–1971. doi:10.1111/cas.15337
9. Zhang X, Fang Y, Zhao Y, Zheng W. Fenbendazole induces apoptosis and cell cycle arrest of tumour cells by inhibiting the polymerisation of tubulin. Oncol Rep. 2023;49(2):41. doi:10.3892/or.2023.8478
10. OneDayMD Editorial Team. Fenbendazole and ivermectin for pancreatic cancer: 46 case reports. OneDayMD.com. 2026. Available: www.onedaymd.com
11. The Cancer Advisor. Advances and emerging therapies in the management of stage 4 pancreatic ductal adenocarcinoma: a comprehensive review. 2025. Available: cancer.aestheticsadvisor.com
12. The Cancer Advisor. Integrative multimodal therapy incorporating repurposed antiparasitic agents, vitamin C, pancreatic enzymes, berberine, and metabolic interventions versus standard chemotherapy in non-BRCA-mutated stage 4 pancreatic cancer: an AI-simulated randomised controlled trial. 2025. Available: cancer.aestheticsadvisor.com
13. American Association for Cancer Research. Pancreatic cancer survivor: Dr Humberto M. Guiot — targeting pancreatic cancer in a community-based clinical trial. AACR Cancer Progress Report. 2024. Available: cancerprogressreport.aacr.org
14. Makis W. Ivermectin Cancer Clinic: Case testimonials series. Substack. 2024–2026. Available: makismd.substack.com.
15. Supple W. 49 People With Pancreatic Cancer Who Beat the Death Sentence. Available: fenbendazole.substack.com.
16. OneDayMD's Newsletter. Ivermectin, Fenbendazole and Mebendazole for Stage 4 Pancreatic Cancer: 29 Case Reports Compilation (2026). Available: onedaymd.substack.com.

© 2026 OneDayMD  |  One Day Media Network  |  www.onedaymd.com

This article is open-access for non-commercial educational use with attribution.  •  Last updated: 15 June 2026